Borella Fulvio, Bertero Luca, Morrone Antonio, Gambella Alessandro, Bovetti Marialuisa, Cosma Stefano, Carosso Andrea, Katsaros Dionyssios, Gemmiti Silvia, Preti Mario, Valabrega Giorgio, Scotto Giulia, Cassoni Paola, Benedetto Chiara
Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.
Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Cancers (Basel). 2020 Aug 4;12(8):2156. doi: 10.3390/cancers12082156.
With this review, we provide the state of the art concerning brain metastases (BMs) from ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features, treatment options, and future perspectives are comprehensively discussed. Overall, a diagnosis of high-grade serous OC and an advanced disease stage are common features among patients who develop brain metastases. and gene mutations, as well as the expression of androgen receptors in the primary tumor, are emerging risk and prognostic factors which could allow one to identify categories of patients at greater risk of BMs, who could benefit from a tailored follow-up. Based on present data, a multidisciplinary approach combining surgery, radiotherapy, and chemotherapy seem to be the best approach for patients with good performance status, although the median overall survival (<1 year) remains largely disappointing. Hopefully, novel therapeutic avenues are being explored, like PARP inhibitors and immunotherapy, based on our improved knowledge regarding tumor biology, but further investigation is warranted.
在本综述中，我们介绍了卵巢癌（OC）脑转移（BMs）这一罕见病症的最新情况。对其临床、病理和分子特征、治疗选择及未来前景进行了全面讨论。总体而言，发生脑转移的患者常见的特征是高级别浆液性OC诊断及疾病晚期。以及基因突变，还有原发肿瘤中雄激素受体的表达，正成为风险和预后因素，这有助于识别发生BMs风险更高的患者类别，这些患者可能从针对性的随访中获益。基于现有数据，对于身体状况良好的患者，手术、放疗和化疗相结合的多学科方法似乎是最佳方法，尽管中位总生存期（<1年）仍然令人失望。令人期待的是，基于我们对肿瘤生物学的深入了解，正在探索新的治疗途径，如PARP抑制剂和免疫疗法，但仍需进一步研究。
